Similarly, the role of hyperglucagonemia in human diabetes may also extend to companion animals, positioning glucagon suppression (via GLP-1 analogs or amylin mimetics) as a potential cross-species therapeutic strategy. Here, IAPP is linked to diabetes mellitus.